Medyczne zastosowania laktoferyny

• Authors: Przemysław Gajda-Morszewski , Klaudyna Śpiewak
• Languages of publication: PL

Abstracts

PL

Laktoferyna, białko wydzielnicze występujące w dużym stężeniu w siarze i mleku, w mniejszym w ślinie, łzach, nasieniu, śluzie itd., od lat przyciąga uwagę badaczy ze względu na szerokie spektrum działania. Przypisuje się jej działanie antybakteryjne, przeciwgrzybicze, antywirusowe, immunomodulacyjne, przeciwnowotworowe oraz wiele innych. W poniższym artykule opisano wyniki najnowszych badań dotyczących medycznych zastosowań laktoferyny. Białko to jest niezwykle interesujące ze względu na różnorodność pełnionych funkcji przy jednoczesnym braku toksyczności, czego dowodem jest posiadanie certyfikatu GRAS (Generally Recognized as Safe).

EN

Lactoferrin is a secreted protein found in high concentrations in colostrum and milk, less aboundant in saliva, tears, semen and mucus etc. etc., has been attracting the attention of researchers because of the broad spectrum of action. Lactoferrin has an antibacterial, antifungal, antiviral, immunomodulatory, antineoplastic activity and many others. The following article describes the results of recent research on medical applications of lactoferrin. This protein is very interesting because of the variety of functions performed in the absence of toxicity, as evidenced by the certificates have GRAS (Generally Recognized as Safe).

Keywords

EN

HIV; bacteria; bakteria; bovine lactoferrin (bLf); bydlęca laktoferyna (bLf); fungi; lactoferricin; lactofferin (Lf); laktoferycyna; laktoferyna (Lf); sepsa; sepsis

Discipline

• MEDICINE: MEDICINE

• Publisher: Towarzystwo Doktorantów. Uniwersytet Jagielloński
• Journal: Zeszyty Naukowe Towarzystwa Doktorantów Uniwersytetu Jagiellońskiego. Nauki Ścisłe
• Year: 2015
• Issue: 11
• Pages: 67-75

Contributors

author

Przemysław Gajda-Morszewski

• Uniwersytet Jagielloński

author

Klaudyna Śpiewak

• Uniwersytet Jagielloński

References

• Actor J. K., Hwang S.-A., Kruzel M. L., Lactoferrin as A Natural Immune Modulator, “Current Pharmaceutical Design” 2009, No. 15, s. 1956–1973.
• Akin I. M. et al., Oral Lactoferrin to Prevent Nosocomial Sepsis and Necrotizing Enterocolitis of Premature Neonates and Effect on T-regulatory Cells, “American Journal of Perinatology” 2014, No. 31, s. 1111–1120
• Ammons M. C., Copié V., Mini-review: Lactoferrin: A Bioinspired, Anti-biofilm Therapeutic, “Biofouling” 2013, No. 29, s. 443–455.
• Berkhout B. et al., Characterization of the Anti-HIV Effects of Native Lactoferrin and Other Milk Proteins and Protein-derived Peptides, “Antiviral Research” 2002, No. 55, s. 341–355.
• Farnaud S., Evans R. W., Lactoferrin – A Multifunctional Protein with Antimicrobial Properties, “Molecular Immunology” 2003, No. 40, s. 395–405.
• Florian P. E., Lazar C., Nichita N., Roseanu A., [w:] Viral Infections: Causes, Treatment Options and Potential Complications, Nova Science Publishers, Inc. 2014, s. 205–246.
• Godoy-Gallardo M. et al., Covalent Immobilization of hLf1-11 Peptide on a Titanium Surface Reduces Bacterial Adhesion and Biofilm Formation, „Acta Biomaterialia” 2014, No. 10, s. 3522–3534.
• González-Chávez S. A., Arévalo-Gallegos S., Rascón-Cruz Q., Lactoferrin: Structure, Function and Applications, “International Journal of Antimicrobial Agents” 2009, No. 33, s. 301.e1–8.
• Greenspan D., Greenspan J. S., HIV-related Oral Disease, “Lancet” 1996, No. 348, s. 729–733.
• Kaur G., Gathwala G., Efficacy of Bovine Lactoferrin Supplementation in Preventing Late-onset Sepsis in low Birth Weight Neonates: A Randomized Placebo-Controlled Clinical Trial, “Journal of Tropical Pediatrics” 2015, No. 61, s. 370–376.
• Lupetti A. et al., Human Lactoferrin-derived Peptide’s Antifungal Activities Against Disseminated Candida Albicans Infection, “Journal of Infectious Diseases” 2007, No. 196, s. 1416–1424
• Małaczewska J., Rotkiewicz Z., Laktoferyna – białko multipotencjalne, „Medycyna Weterynaryjna” 2007, nr 63, s. 136–139.
• Manzoni P. et al., Bovine Lactoferrin Supplementation for Prevention of Necrotizing Enterocolitis in Very-low-birth-weight Neonates: A Randomized Clinical Trial, “Early Human Development” 2014, No. 90, s. S60–S65.
• Manzoni P. et al., Bovine Lactoferrin Supplementation for Prevention of Late-onset Sepsis in Very Low-birth-weight Neonates: A Randomized Trial, “JAMA” 2009, No. 302, s. 1421–1428.
• Manzoni P. et al., Clinical Use of Lactoferrin in Preterm Neonates: An Update, “Minerva pediatrica” 2010, No. 62, s. 101–104.
• Manzoni P. et al., Lactoferrin and Prevention of Late-onset Sepsis in the Pre-term Neonates, “Early Human Development” 2010, No. 86, Suppl. 1, s. 59–61
• Manzoni P. et. al., Bovine Lactoferrin Prevents Invasive Fungal Infections in Very Low Birth Weight Infants: A Randomized Controlled Trial, “Pediatrics” 2012, No. 129, s. 1–10.
• Mohan P., Abrams S. A., Oral Lactoferrin for the Treatment of Sepsis and Necrotizing Enterocolitis in Neonates, “Cochrane Database of Systematic Reviews” 2009, doi:10.1002/14651858.CD007138.pub2.
• Ochoa T. J. et al., Randomized Controlled Trial of Lactoferrin for Prevention of Sepsis in Peruvian Neonates Less than 2500 g, “Pediatric Infectious Disease Journal” 2015, No. 34, s. 571–576.
• Pammi M., Abrams S. A., Oral Lactoferrin for the Treatment of Sepsis and Necrotizing Enterocolitis in Neonates, “Cochrane Database of Systematic Reviews” 2011.
• Rodríguez-Franco D. A., Vázquez-Moreno L., Ramos-Clamont Montfort G., Antimicrobial Activity of Lactoferrin: Mechanisms and Possible Clinical Applications, “Revista Latinoamericana de Microbiologia” 2005, No. 47, s. 102–111.
• Sanchez L., Calvo M., Brock J. H., Biological Role of Lactoferrin, “Archives of Disease in Childhood” 1992, No. 67, s. 657–661
• Suerbaum S., Michetti P., Helicobacter Pylori Infection, “The New England Journal of Medicine” 2002, No. 347, s. 1175–1186.
• Tolone S., Pellino V., Vitaliti G., Lanzafame A., Tolone C., Evaluation of Helicobacter Pylori Eradication in Pediatric Patients by Triple Therapy Plus Lactoferrin and Probiotics Compared to Triple Therapy Alone, “Italian Journal of Pediatrics” 2012, No. 38, s. 63.
• Valenti P., Visca P., Antonini G., Orsi N., Interaction between Lactoferrin and Ovotransferrin and Candida Cells, “FEMS Microbiology Letters” 1986, No. 33, s. 271–275.
• Yamauchi K., Tomita M., Giehl T. J., Ellison III R. T., Antibacterial Activity of Lactoferrin and a Pepsin-derived Lactoferrin Peptide Fragment, “Infection and Immunity” 1993, No. 61, s. 719–728.
• Zuccotti G. V. et al., Modulation of Innate and Adaptive Immunity by Lactoferrin in Human Immunodeficiency Virus (HIV)-infected, Antiretroviral Therapy-naïve Children, “International Journal of Antimicrobial Agents” 2007, No. 29, s. 353–355.
• Zuccotti G. V., Salvini F., Riva E., Agostoni C., Oral Lactoferrin in HIV-1 Vertically Infected Children: An Observational Follow-up of Plasma Viral Load and Immune Parameters, “Journal of International Medical Research” 2006, No. 34, s. 88–94.

• Document Type: article